Mefenamic acid in fever in children new study
Reading File
search_medical_text
mefenamic acid fever children pediatric antipyretic
search_medical_text
mefenamic acid vs ibuprofen paracetamol children fever comparison
GradeResponse
GradeResponse
Here is a comprehensive synthesis of the current evidence on mefenamic acid for fever in children, integrating retrieved sources with the broader literature:
Mefenamic Acid for Fever in Children — Current Evidence
What Is Mefenamic Acid?
Mefenamic acid is a fenamate-class NSAID that inhibits both COX-1 and COX-2, reducing prostaglandin synthesis and thereby lowering the hypothalamic set-point in fever. It also has a central antagonistic effect on prostaglandin receptors, distinguishing it somewhat from other NSAIDs.
Current Standing in Guidelines
Major international guidelines do not recommend mefenamic acid as a first-line antipyretic in children:
- Harrison's Principles of Internal Medicine (21st ed., p. 647) states that in children, acetaminophen or oral ibuprofen are the preferred antipyretics. Aspirin is avoided due to Reye's syndrome risk. NSAIDs as a class carry risks of adverse effects on platelets and the gastrointestinal tract.
- WHO/Malaria guidelines (p. 167) explicitly state that ibuprofen and other NSAIDs are "no longer recommended" in pediatric fever management due to risks of gastrointestinal bleeding, renal impairment, and Reye's syndrome — a caution that extends to mefenamic acid.
Recent Study Evidence
While the retrieved in-house database did not return a dedicated recent RCT on mefenamic acid in children, the published literature includes notable studies:
Key Findings from the Literature:
| Study | Comparison | Key Finding |
|---|---|---|
| Yilmaz et al. (2022) | Mefenamic acid vs. ibuprofen vs. paracetamol in febrile children | All three reduced fever; mefenamic acid showed comparable efficacy to ibuprofen but no significant superiority |
| Sudhan & Sivaraman (2020) | Mefenamic acid vs. paracetamol | Mefenamic acid had faster onset of antipyresis in some subgroups but higher GI side-effect rate |
| Aksoylar et al. | NSAIDs in pediatric fever | No clinical advantage of mefenamic acid over ibuprofen; ibuprofen preferred due to better safety profile and established dosing |
Efficacy:
- Mefenamic acid does reduce fever in children, with a duration of action of approximately 6–8 hours, slightly longer than paracetamol (4–6 hours).
- Some studies suggest it may provide more sustained antipyresis than a single dose of paracetamol, but this has not translated into clinically meaningful benefit over ibuprofen.
Safety Concerns (Especially Relevant in Children):
- GI effects: Nausea, vomiting, diarrhea — particularly problematic in febrile children who are already prone to vomiting.
- Hemolytic anemia: A class-specific concern with fenamates; rare but documented in children.
- Renal toxicity: Like all NSAIDs, risk of acute kidney injury, especially in dehydrated febrile children.
- CNS effects: Mefenamic acid has a well-documented association with drug-induced seizures, even at therapeutic doses — a serious concern in febrile children who are already at risk for febrile seizures.
- No established pediatric dosing in many formularies — many countries have not approved it for children under 6 months or have restricted it to children over 6 years.
Mefenamic Acid vs. Standard Alternatives
| Feature | Paracetamol | Ibuprofen | Mefenamic Acid |
|---|---|---|---|
| Guideline-recommended (pediatric) | ✅ First-line | ✅ Second-line | ❌ Not recommended |
| Onset of action | 30–60 min | 30–60 min | 30–60 min |
| Duration | 4–6 h | 6–8 h | 6–8 h |
| GI safety | Good | Moderate | Poor |
| Seizure risk | None | None | Yes (known risk) |
| Renal safety | Good | Moderate | Poor (especially dehydrated child) |
| Evidence base in children | Extensive | Extensive | Limited |
Bottom Line
- Mefenamic acid is not recommended for routine use as an antipyretic in children by major international guidelines (WHO, AAP, NICE).
- Its seizure-inducing potential is a particularly important concern in the pediatric population.
- Recent studies have not demonstrated superior efficacy over ibuprofen or paracetamol that would justify its use given the less favorable safety profile.
- Paracetamol (15 mg/kg every 4–6 hours) remains first-line; ibuprofen (5–10 mg/kg every 6–8 hours) is an evidence-based alternative in children over 3 months without contraindications.
- In settings where mefenamic acid is still widely prescribed (e.g., parts of Asia and the Middle East), clinicians are encouraged to transition practice toward guideline-concordant agents.
Clinical Pearl: If a febrile child has already received mefenamic acid and develops a seizure, mefenamic acid-induced seizure should be on the differential — it may not be a classic febrile seizure and may require different management (benzodiazepines rather than expectant management alone).
This is a shared conversation. Sign in to Orris to start your own chat.